curasan develops, produces and markets medical products in the area of bone and tissue regeneration. As a global technology leader, our company specializes in the future-oriented growth market of regenerative medicine specializes primarily in synthetic bone replacement materials for use in orthopedics and dental implantology. Its portfolio includes: Cerasorb, a synthetic bone substitution and regeneration material; stypro, a haemostyptic gelatin sponge for wound healing; and Curavisc, a hyaluronic acid for the treatment of osteoarthritis; as well as the dental product line acquired from Riemser Pharma GmbH, and a dental implantology product Osgide, a biodegradable barrier membrane to be used in guided tissue regeneration (GTR) and guided bone regeneration (GBR), among others. The Company has two subsidiaries operating in Germany and the United States.
Type
Public
HQ
Kleinostheim, DE
Founded
1988
Employees
33 (est)

Curasan Locations

Kleinostheim, DE

Curasan Metrics

Curasan Summary

Founding Date

1988

Market capitalization

€9.83 M

Closing share price

€0.96

Curasan Market Value History

Market Position – Health, regeneration

Curasan Company Life